TG Therapeutics (TGTX) Coverage Initiated at B. Riley

Research analysts at B. Riley assumed coverage on shares of TG Therapeutics (NASDAQ:TGTX) in a research report issued on Friday. The firm set a “buy” rating and a $21.50 price target on the biopharmaceutical company’s stock. B. Riley’s target price would indicate a potential upside of 158.26% from the stock’s current price.

TGTX has been the subject of a number of other reports. BidaskClub upgraded TG Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 24th. SunTrust Banks restated a “buy” rating and set a $28.00 price objective on shares of TG Therapeutics in a report on Tuesday, October 3rd. HC Wainwright restated a “buy” rating and set a $33.00 price objective (up from $18.00) on shares of TG Therapeutics in a report on Tuesday, November 14th. ValuEngine downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, October 16th. Finally, Zacks Investment Research downgraded TG Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, August 4th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and ten have assigned a buy rating to the company. TG Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $26.25.

TG Therapeutics (NASDAQ TGTX) opened at $8.33 on Friday. TG Therapeutics has a twelve month low of $4.10 and a twelve month high of $15.35.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.05). The business had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.04 million. TG Therapeutics had a negative net margin of 73,217.77% and a negative return on equity of 151.21%. equities analysts expect that TG Therapeutics will post -1.86 EPS for the current fiscal year.

Several hedge funds have recently added to or reduced their stakes in TGTX. Legal & General Group Plc boosted its position in TG Therapeutics by 4.1% during the 1st quarter. Legal & General Group Plc now owns 9,801 shares of the biopharmaceutical company’s stock worth $113,000 after purchasing an additional 384 shares during the period. Bank of America Corp DE boosted its position in TG Therapeutics by 11.0% during the 1st quarter. Bank of America Corp DE now owns 14,076 shares of the biopharmaceutical company’s stock worth $164,000 after purchasing an additional 1,395 shares during the period. BB&T Securities LLC boosted its position in TG Therapeutics by 63.0% during the 2nd quarter. BB&T Securities LLC now owns 16,949 shares of the biopharmaceutical company’s stock worth $170,000 after purchasing an additional 6,549 shares during the period. UBS Group AG boosted its position in TG Therapeutics by 34.4% during the 1st quarter. UBS Group AG now owns 14,606 shares of the biopharmaceutical company’s stock worth $171,000 after purchasing an additional 3,736 shares during the period. Finally, First Mercantile Trust Co. boosted its position in TG Therapeutics by 199.7% during the 2nd quarter. First Mercantile Trust Co. now owns 19,179 shares of the biopharmaceutical company’s stock worth $193,000 after purchasing an additional 12,779 shares during the period. Institutional investors and hedge funds own 50.45% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.com-unik.info/2017/12/03/tg-therapeutics-tgtx-coverage-initiated-at-b-riley.html.

TG Therapeutics Company Profile

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Analyst Recommendations for TG Therapeutics (NASDAQ:TGTX)

What are top analysts saying about TG Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for TG Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit